Base de dados : MEDLINE
Pesquisa : D03.383.710.100 [Categoria DeCS]
Referências encontradas : 534 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 54 ir para página                         

  1 / 534 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25890215
[Au] Autor:Narayanam M; Sahu A; Singh S
[Ad] Endereço:Biocon-BMS R&D Centre (BBRC), Biocon Park, Bangalore, India.
[Ti] Título:Use of LC-MS/TOF, LC-MS(n), NMR and LC-NMR in characterization of stress degradation products: Application to cilazapril.
[So] Source:J Pharm Biomed Anal;111:190-203, 2015.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Forced degradation studies on cilazapril were carried out according to ICH and WHO guidelines. Significant degradation of the drug was observed in acid and base conditions, resulting primarily in cilazaprilat. In neutral condition, five degradation products were formed, while under oxidative condition, two degradation products were generated. In total, seven degradation products were formed, which were separated on an Inertsil C-18 column using a stability-indicating HPLC method. Structure elucidation of the degradation products was done by using sophisticated and hyphenated tools like, LC-MS/TOF, LC-MS(n), on-line H/D exchange, LC-NMR and NMR. Initially, comprehensive mass fragmentation pathway of the drug was laid down. Critical comparison of mass fragmentation pathways of the drug and its hydrolytic degradation products allowed structure characterization of the latter. 1D and 2D proton LC-NMR studies further confirmed the proposed structures of hydrolytic degradation products. The oxidative degradation products could not be characterized using LC-MS and LC-NMR tools. Hence, these degradation products were isolated using preparative HPLC and extensive 1D ((1)H, (13)C, DEPT) and 2D (COSY, TOCSY, HETCOR and HMBC) NMR studies were performed to ascertain their structures. Finally, degradation pathways and mechanisms of degradation of the drug were outlined.
[Mh] Termos MeSH primário: Cilazapril/análogos & derivados
[Mh] Termos MeSH secundário: Cromatografia Líquida de Alta Pressão/métodos
Cilazapril/química
Estabilidade de Medicamentos
Hidrólise
Espectroscopia de Ressonância Magnética/métodos
Espectrometria de Massas/métodos
Oxirredução
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
19KW7PI29F (Cilazapril); WBL76FH528 (cilazaprilat)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:150521
[Lr] Data última revisão:
150521
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150419
[St] Status:MEDLINE


  2 / 534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25272892
[Au] Autor:Stanisz BJ; Paszun SK; Zalewska A
[Ti] Título:Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms.
[So] Source:Acta Pol Pharm;71(4):661-6, 2014 Jul-Aug.
[Is] ISSN:0001-6837
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Abstract: Cilazapril is a drug commonly used in management of heart failure in pediatric population. On pharmaceutical market it is available only in inconvenient for pediatric use tablet dosage forms. Until now, no oral liquid formulation containing cilazapril has been evaluated. Therefore, the aim of this study was to prepare easy to made and palatable 1 mg/mL oral liquid formulation with cilazapril (with consideration of original and generic cilazapril tablet and different packages) and subsequent investigation of physicochemical stability of these suspensions. Formulations were compounded using cilazapril obtained from original or generic cilazapril marketed tablet formulations and Ora-Blend" suspending agent. Stability of prepared suspensions stored in closed amber glass or amber plastic PET bottles in the temperature of 298 K was estimated throughout 28 day shelf-life period. Chemical stability was assessed by HPLC cilazapril stability indicating method. Physical stability was evaluated by appearance, taste, smell, pH and theological assessments. Cilazapril oral suspensions at concentration of 1 mg/mL demonstrated satisfactory stability over 28 day long storage at room temperature. Cilazapril concentrations remained within acceptable limit (+/- 10%) stored in closed amber bottles made of glass or PET material. Moreover, suspensions physical properties remained unaffected. Cilazapril - Ora-Blend* pediatric oral liquid is easy to made, palatable and stable when stored at room temperature for 28 days. Stability of cilazapril oral liquid remains unchanged while using cilazapril tablets produced by different manufacturers and bottles made of amber glass or PET material.
[Mh] Termos MeSH primário: Cilazapril/química
[Mh] Termos MeSH secundário: Química Farmacêutica
Cromatografia Líquida de Alta Pressão
Cilazapril/análise
Estabilidade de Medicamentos
Suspensões
Comprimidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Suspensions); 0 (Tablets); 19KW7PI29F (Cilazapril)
[Em] Mês de entrada:1411
[Cu] Atualização por classe:141002
[Lr] Data última revisão:
141002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141003
[St] Status:MEDLINE


  3 / 534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24862968
[Au] Autor:Zhang L; Hao JB; Ren LS; Ding JL; Hao LR
[Ad] Endereço:The Second Ward of the Department of Nephrology, First Affiliated Hospital of Harbin Medical University, Harbin, China.
[Ti] Título:The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis.
[So] Source:Lab Invest;94(8):839-50, 2014 Aug.
[Is] ISSN:1530-0307
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Peritoneal fibrosis is a complication of patients with long-term continuous ambulatory peritoneal dialysis (CAPD). Reports have indicated that angiotensin (Ang) II may correlate with the development of peritoneal fibrosis. However, it is unknown whether aldosterone also has a role in the development of peritoneal inflammation and fibrosis. The aim of the present study was to clarify the role of aldosterone in peritoneal inflammation and fibrosis. A rat model of peritoneal inflammation and fibrosis was established by daily intraperitoneal injection of dialysates and lipopolysaccharide in a 4-day interval over a period of 7 days. The animals were randomly assigned to five groups as follows: control (C); peritoneal dialysis (PD); peritoneal dialysis-spironolactone (PD-S); peritoneal dialysis-cilazapril (PD-C); and peritoneal dialysis-spironolactone-cilazapril (PD-SC). After 30 days, the TGF-ß1 concentration in dialysates from all treatment groups was determined by ELISA. The histopathology of the parietal peritoneum was examined, and the expression of MCP-1, c-Jun, fibronectin (FN) and TGF-ß1 in the abdominal membrane was determined by immunohistochemistry. Mineralocorticoid receptor (MR), 11ß-hydroxysteroid dehydrogenase type 2 (11ß-HSD2) and CYP11B2 (aldosterone synthase) were analyzed by real time-PCR. Collagen deposition was significantly higher in PD compared with the other groups. The expression of MR, 11ß-HSD2 and CYP11B2 was significantly higher in PD compared with the other groups. Spironolactone and/or cilazapril treatment partially ablated the increase in monocyte chemoattractant protein (MCP)-1, p-c-Jun, transforming growth factor (TGF)-ß1, FN, MR, 11ß-HSD2 and CYP11B2. Furthermore, treatment with spironolactone and/or cilazapril also reduced the infiltration of CD-4- and ED-1-positive cells in rat peritoneal tissues after peritoneal fibrosis. Exogenous aldosterone may have a key role in the development of peritoneal inflammation and fibrosis. Spironolactone decreased peritoneal inflammation and fibrosis, which was associated with reduced secretion from peritoneal macrophages, inactivation of the c-Jun N-terminal kinase (JNK) pathway and subsequent downregulation of the expression of TGF-ß1.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Modelos Animais de Doenças
Antagonistas de Receptores de Mineralocorticoides/uso terapêutico
Fibrose Peritoneal/prevenção & controle
Peritônio/efeitos dos fármacos
Peritonite/prevenção & controle
Espironolactona/uso terapêutico
[Mh] Termos MeSH secundário: Aldosterona/química
Aldosterona/metabolismo
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Animais
Cilazapril/uso terapêutico
Soluções para Diálise/química
Quimioterapia Combinada
Linfócitos/efeitos dos fármacos
Linfócitos/imunologia
Linfócitos/metabolismo
Linfócitos/patologia
Macrófagos/efeitos dos fármacos
Macrófagos/imunologia
Macrófagos/metabolismo
Macrófagos/patologia
Masculino
Diálise Peritoneal Ambulatorial Contínua/efeitos adversos
Fibrose Peritoneal/etiologia
Fibrose Peritoneal/imunologia
Fibrose Peritoneal/patologia
Peritônio/imunologia
Peritônio/metabolismo
Peritônio/patologia
Peritonite/etiologia
Peritonite/imunologia
Peritonite/patologia
Distribuição Aleatória
Ratos
Ratos Wistar
Receptores de Mineralocorticoides/química
Receptores de Mineralocorticoides/metabolismo
Fator de Crescimento Transformador beta1/análise
Fator de Crescimento Transformador beta1/antagonistas & inibidores
Fator de Crescimento Transformador beta1/metabolismo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Anti-Inflammatory Agents); 0 (Dialysis Solutions); 0 (Mineralocorticoid Receptor Antagonists); 0 (Receptors, Mineralocorticoid); 0 (Tgfb1 protein, rat); 0 (Transforming Growth Factor beta1); 19KW7PI29F (Cilazapril); 27O7W4T232 (Spironolactone); 4964P6T9RB (Aldosterone)
[Em] Mês de entrada:1409
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140528
[St] Status:MEDLINE
[do] DOI:10.1038/labinvest.2014.69


  4 / 534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24383331
[Au] Autor:Paszun SK; Stanisz BJ; Gradowska A
[Ad] Endereço:Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 6 Grunwaldzka St., 60-780 Poznan, Poland.
[Ti] Título:Cilazapril stability in the presence of hydrochlorothiazide in model mixtures and fixed dose combination.
[So] Source:Acta Pol Pharm;70(6):1079-85, 2013 Nov-Dec.
[Is] ISSN:0001-6837
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:The presented study aimed at the evaluation of hydrochlorothiazide influence on cilazapril stability in model mixture and fixed dose tablet formulation. The degradation of cilazapril in the presence of hydrochlorothiazide took place according to autocatalytic reaction kinetic mechanism, described mathematically by Prout-Tompkins equation. Hydrochlorothiazide coexistence with cilazapril in model mixture and fixed dose tablet without blister package accelerated cilazapril degradation in comparison with degradation of cilazapril substance. Values of reaction induction time shortened, while those of observed reaction rate constant increased. Increasing values of relative humidity and temperature have negative impact on cilazapril stability. Determined semi-logarithmic relationships: In k = f(RH) and Arrhenius ln k = f(1/T) are linear and are cilazapril stability predictive. The blister (OPA/Alu/PVC//Alu) package of fixed dose tablets, constitutes absolute moisture protection and prevent cilazapril--hydrochlorothiazide interaction occurrence.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/química
Anti-Hipertensivos/química
Cilazapril/química
Diuréticos/química
Hidroclorotiazida/química
[Mh] Termos MeSH secundário: Catálise
Química Farmacêutica
Cromatografia Líquida de Alta Pressão
Combinação de Medicamentos
Embalagem de Medicamentos
Estabilidade de Medicamentos
Armazenamento de Medicamentos
Cinética
Modelos Químicos
Comprimidos
Tecnologia Farmacêutica/métodos
Água/química
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Antihypertensive Agents); 0 (Diuretics); 0 (Drug Combinations); 0 (Tablets); 059QF0KO0R (Water); 0J48LPH2TH (Hydrochlorothiazide); 19KW7PI29F (Cilazapril)
[Em] Mês de entrada:1402
[Cu] Atualização por classe:140103
[Lr] Data última revisão:
140103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140104
[St] Status:MEDLINE


  5 / 534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24145096
[Au] Autor:Lukawski K; Jakubus T; Janowska A; Raszewski G; Czuczwar SJ
[Ad] Endereço:Department of Physiopathology, Institute of Agricultural Medicine, Jaczewskiego 2, PL 20-090 Lublin, Poland. lukaw@mp.pl.
[Ti] Título:Enalapril enhances the anticonvulsant activity of lamotrigine in the test of maximal electroshock.
[So] Source:Pharmacol Rep;65(4):1012-7, 2013.
[Is] ISSN:1734-1140
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The aim of this study was to find out whether angiotensin-converting enzyme (ACE) inhibitors, enalapril and cilazapril, affect the anticonvulsant action of some second-generation antiepileptics, lamotrigine (LTG), topiramate (TPM) and oxcarbazepine (OXC). METHODS: The effects of ACE inhibitors on antiepileptic drugs were examined in the mouse model of maximal electroshock. RESULTS: Enalapril (30 mg/kg ip) potentiated the anticonvulsant action of LTG, decreasing its ED50 value from 5.3 to 3.6 mg/kg (p < 0.01). The anticonvulsant activity of TPM or OXC was not modified by enalapril. Cilazapril did not affect the protective activity of the studied antiepileptics. The interaction between enalapril and LTG could be pharmacodynamic in nature because enalapril did not change plasma and total brain concentrations of LTG. CONCLUSIONS: This study shows that there are no negative interactions between the studied antiepileptic drugs and enalapril or cilazapril. Enalapril even enhanced the anticonvulsant activity of LTG in the MES test in mice that is thought to be a predictive model of human generalized tonic-clonic seizures.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/farmacologia
Anticonvulsivantes/farmacologia
Sinergismo Farmacológico
Enalapril/farmacologia
Triazinas/farmacologia
[Mh] Termos MeSH secundário: Animais
Carbamazepina/análogos & derivados
Carbamazepina/farmacologia
Cilazapril/farmacologia
Eletrochoque
Frutose/análogos & derivados
Frutose/farmacologia
Masculino
Camundongos
Desempenho Psicomotor/efeitos dos fármacos
Triazinas/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Anticonvulsants); 0 (Triazines); 0H73WJJ391 (topiramate); 19KW7PI29F (Cilazapril); 30237-26-4 (Fructose); 33CM23913M (Carbamazepine); 69PN84IO1A (Enalapril); U3H27498KS (lamotrigine); VZI5B1W380 (oxcarbazepine)
[Em] Mês de entrada:1406
[Cu] Atualização por classe:131022
[Lr] Data última revisão:
131022
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131023
[St] Status:MEDLINE


  6 / 534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23477013
[Au] Autor:Cutfield NI; Tong DC
[Ad] Endereço:Sir John Walsh Research Institute, Department of Oral Diagnostic and Surgical Sciences, School of Dentistry, The University of Otago, Dunedin.
[Ti] Título:Common medications among dental outpatients: considerations in general dental practice.
[So] Source:N Z Dent J;108(4):140-7, 2012 Dec.
[Is] ISSN:0028-8047
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To provide information about the most common medications listed as being taken by dental patients presenting to an outpatient setting at a tertiary institution and to establish a list of the most common medications for review for the general dental practitioner. METHODS: A retrospective review was undertaken of 300 dental outpatient notes chosen from patients seen in the urgent dental care and exodontia clinics at the School of Dentistry in Dunedin. Data were recorded on patient age, medication list reported at the time of presentation and the number of medications. The ten most common medications encountered were listed in order of frequency, along with the ten most common prescription medications and the most common supplements or alternative remedies. A concise pharmacological synopsis for each of the ten most common medications was then presented as a review. RESULTS: The age range of patients was from 18 to 88 years, with a mean age of 43.2 years (median age 41 years). More than one-quarter were aged 20-29 years. Some 56% of patients reported taking at least one medication at the time of presentation. The greatest number of medications being taken by an individual patient was 15. Of 138 different medications identified, the most commonly reported included aspirin, paracetamol and omeprazole. A list of the ten most common medications was established for concise review, in order to outline aspects important to the general dental practitioner. CONCLUSIONS: This study provides information on the most common medications reported among dental outpatients presenting to a tertiary institution and highlights the need for general dental practitioners to be knowledgeable about them and their impact on dental treatment.
[Mh] Termos MeSH primário: Clínicas Odontológicas
Uso de Medicamentos
Odontologia Geral
Pacientes Ambulatoriais/estatística & dados numéricos
[Mh] Termos MeSH secundário: Acetaminofen/uso terapêutico
Adolescente
Adulto
Distribuição por Idade
Idoso
Analgésicos não Entorpecentes/uso terapêutico
Anti-Inflamatórios não Esteroides/uso terapêutico
Antiulcerosos/uso terapêutico
Anti-Hipertensivos/uso terapêutico
Aspirina/uso terapêutico
Cilazapril/uso terapêutico
Interações Medicamentosas
Uso de Medicamentos/estatística & dados numéricos
Feminino
Seres Humanos
Masculino
Meia-Idade
Nova Zelândia
Omeprazol/uso terapêutico
Polimedicação
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Non-Narcotic); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Anti-Ulcer Agents); 0 (Antihypertensive Agents); 19KW7PI29F (Cilazapril); 362O9ITL9D (Acetaminophen); KG60484QX9 (Omeprazole); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1304
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:130313
[St] Status:MEDLINE


  7 / 534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:22568033
[Au] Autor:Paszun SK; Stanisz B; Pawlowski W
[Ad] Endereço:Department of Pharmaceutical Chemistry, K. Marcinkowski University of Medical Sciences, 6 Grunwaldzka St., 60-780 Poznan, Poland.
[Ti] Título:Rapid and simple stability indicating HPLC method for the determination of cilazapril in pure substance and pharmaceutical formulation in comparison with classic and derivative spectrophotometric methods.
[So] Source:Acta Pol Pharm;69(2):193-201, 2012 Mar-Apr.
[Is] ISSN:0001-6837
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:The present study describes development and subsequent validation of high performance liquid chromatographic method (HPLC) in comparison with spectrophotometric methods (classic, first, second and third order derivative) for determination of pure cilazapril in substance and pharmaceutical preparation. The main aim of this study was to find the method suitable not only for determination of cilazapril, but additionally useful in degradation kinetic study. Only the HPLC method is stability indicating. The HPLC method utilizes LiChroCART 250-4 HPLC-Cartridge, LiChrospher 100 RP-18 (5 µm) column, at ambient temperature, eluted at the flow rate 1.0 mL/min. The mobile phase consists of acetonitrile, methanol and phosphate buffer (pH 2.0) (60:10:30, v/v/v). Wavelength of detection is set at 212 nm. Benzocaine is used as an internal standard. The second and third order derivative spectrophotometric methods can be applied for the cilazapril analysis in substance and tablet, but not for stability evaluation (the lack of selectivity towards degradation product).
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/análise
Cromatografia Líquida de Alta Pressão/métodos
Cilazapril/análise
Espectrofotometria/métodos
[Mh] Termos MeSH secundário: Cilazapril/química
Estabilidade de Medicamentos
Preparações Farmacêuticas/análise
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Pharmaceutical Preparations); 19KW7PI29F (Cilazapril)
[Em] Mês de entrada:1205
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120510
[St] Status:MEDLINE


  8 / 534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:21797003
[Au] Autor:Kolocouri F; Dotsikas Y; Apostolou C; Kousoulos C; Soumelas GS; Loukas YL
[Ad] Endereço:University of Athens, Division of Pharmaceutical Chemistry, Department of Pharmacy, Panepistimioupoli Zografou GR-157 71, Athens, Greece.
[Ti] Título:Advantages of automation in plasma sample preparation prior to HPLC/MS/MS quantification: application to the determination of cilazapril and cilazaprilat in a bioequivalence study.
[So] Source:J AOAC Int;94(3):758-64, 2011 May-Jun.
[Is] ISSN:1060-3271
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:An HPLC/MS/MS method characterized by complete automation and high throughput was developed for the determination of cilazapril and its active metabolite cilazaprilat in human plasma. All sample preparation and analysis steps were performed by using 2.2 mL 96 deep-well plates, while robotic liquid handling workstations were utilized for all liquid transfer steps, including liquid-liquid extraction. The whole procedure was very fast compared to a manual procedure with vials and no automation. The method also had a very short chromatographic run time of 1.5 min. Sample analysis was performed by RP-HPLC/MS/MS with positive electrospray ionization using multiple reaction monitoring. The calibration curve was linear in the range of 0.500-300 and 0.250-150 ng/mL for cilazapril and cilazaprilat, respectively. The proposed method was fully validated and proved to be selective, accurate, precise, reproducible, and suitable for the determination of cilazapril and cilazaprilat in human plasma. Therefore, it was applied to a bioequivalence study after per os administration of 2.5 mg tablet formulations of cilazapril.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Cilazapril/análogos & derivados
Cilazapril/química
Espectrometria de Massas em Tandem/métodos
Equivalência Terapêutica
[Mh] Termos MeSH secundário: Inibidores da Enzima Conversora de Angiotensina/química
Inibidores da Enzima Conversora de Angiotensina/farmacocinética
Automação
Cilazapril/administração & dosagem
Cilazapril/farmacocinética
Estabilidade de Medicamentos
Seres Humanos
Estrutura Molecular
Sensibilidade e Especificidade
Manejo de Espécimes/métodos
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 19KW7PI29F (Cilazapril); WBL76FH528 (cilazaprilat)
[Em] Mês de entrada:1108
[Cu] Atualização por classe:140109
[Lr] Data última revisão:
140109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110730
[St] Status:MEDLINE


  9 / 534 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21496825
[Au] Autor:Vovk I; Popovic G; Simonovska B; Albreht A; Agbaba D
[Ad] Endereço:National Institute of Chemistry, Laboratory for Food Chemistry, Ljubljana, Slovenia. irena.vovk@ki.si
[Ti] Título:Ultra-thin-layer chromatography mass spectrometry and thin-layer chromatography mass spectrometry of single peptides of angiotensin-converting enzyme inhibitors.
[So] Source:J Chromatogr A;1218(20):3089-94, 2011 May 20.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The separation of structurally related angiotensin-converting enzyme (ACE) inhibitors lisinopril, cilazapril, ramipril and quinapril and their corresponding active diacid forms (prilates) by conventional TLC silica gel 60 plates was contrasted with that afforded by monolithic ultra-thin-layer chromatographic (UTLC) plates. For the use of UTLC plates technical modifications of the commercially available equipments for the sample application, development and detection were made. Plates were developed in modified horizontal developing chamber using ethyl acetate-acetone-acetic acid-water (4:1:0.25:0.5, v/v). Detection of the separated compounds was performed densitometrically in absorption/reflectance mode at 220 nm and after exposure to iodine also by image analysis. The obtained results showed that monolithic layer is more efficient for the separation of structurally similar polar compounds, such as prilates than conventional silica layers. Identification of the compounds was confirmed by ESI-MS after their on-line extraction from the UTLC and TLC plates by means of Camag TLC-MS interface.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/química
Cromatografia em Camada Delgada/métodos
Peptídeos/química
Espectrometria de Massas por Ionização por Electrospray/métodos
[Mh] Termos MeSH secundário: Cilazapril/química
Densitometria
Processamento de Imagem Assistida por Computador
Lisinopril/química
Ramipril/química
Tetra-Hidroisoquinolinas/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Peptides); 0 (Tetrahydroisoquinolines); 19KW7PI29F (Cilazapril); E7199S1YWR (Lisinopril); L35JN3I7SJ (Ramipril); RJ84Y44811 (quinapril)
[Em] Mês de entrada:1108
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110419
[St] Status:MEDLINE
[do] DOI:10.1016/j.chroma.2011.03.039


  10 / 534 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:20976419
[Au] Autor:Dervis E; Demirkesen C
[Ad] Endereço:Dermatology Department, Haseki Hospital, Istanbul. eminedervis@hotmail.com
[Ti] Título:Kaposi's sarcoma in a patient with psoriasis vulgaris.
[So] Source:Acta Dermatovenerol Alp Pannonica Adriat;19(3):31-4, 2010 Oct.
[Is] ISSN:1581-2979
[Cp] País de publicação:Slovenia
[La] Idioma:eng
[Ab] Resumo:A 54-year-old woman presented with angiomatous lesions located on the upper extremities and right cruris. Histopathological findings were typical of Kaposi's sarcoma (KS). She had had mild to moderate psoriasis since she was 25 years old. She had been using cilazapril (an angiotensin-converting enzyme inhibitor) for the last 9 months. She had had similar lesions in the past while taking the same medication. Because our patient's KS lesions had developed during treatment with cilazapril, the drug was stopped. One month later, spontaneous regression of KS nodules was noted and after 4 months no KS lesions were seen.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/efeitos adversos
Cilazapril/efeitos adversos
Psoríase/tratamento farmacológico
Sarcoma de Kaposi/induzido quimicamente
Sarcoma de Kaposi/patologia
Neoplasias Cutâneas/química
Neoplasias Cutâneas/patologia
[Mh] Termos MeSH secundário: Inibidores da Enzima Conversora de Angiotensina/administração & dosagem
Cilazapril/administração & dosagem
Feminino
Seres Humanos
Meia-Idade
Psoríase/complicações
Sarcoma de Kaposi/complicações
Neoplasias Cutâneas/complicações
Extremidade Superior
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 19KW7PI29F (Cilazapril)
[Em] Mês de entrada:1111
[Cu] Atualização por classe:140530
[Lr] Data última revisão:
140530
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:101027
[St] Status:MEDLINE



página 1 de 54 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde